Phibro Animal Health Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2016. The request metadata references “2015 Q4,” but the supplied filing is the fiscal 2016 Form 10-K, with fiscal 2015 as the primary comparable period.
Business context
Phibro is a global animal health, mineral nutrition and specialty ingredients company operating in more than 65 countries and serving approximately 3,000 customers. Its segments are Animal Health, Mineral Nutrition and Performance Products. Animal Health accounted for approximately 65% of fiscal 2016 sales and includes medicated feed additives, nutritional specialties and vaccines.
Key financial metrics
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Net sales | $751.5 million | $748.6 million | Up 0.4% |
| Gross profit | $239.0 million | $233.3 million | Up 2.5% |
| Gross margin | 31.8% | 31.2% | Up 60 bps |
| Operating income | $85.7 million | $87.7 million | Down 2.2% |
| Operating margin | 11.4% | 11.7% | Down 30 bps |
| Net income | $82.7 million | $60.3 million | Up 37.2% |
| Diluted EPS | $2.07 | $1.51 | Up $0.56 |
| Adjusted EBITDA | $114.1 million | $110.0 million | Up 3.7% |
| Operating cash flow | $37.2 million | $68.7 million | Down $31.5 million |
| Capital expenditures | $36.4 million | $20.1 million | Up $16.3 million |
Animal Health sales increased 3% to $486.1 million, led by nutritional specialties, while Mineral Nutrition sales declined 5% to $216.7 million because lower commodity prices reduced selling prices. Performance Products sales declined 4% to $48.7 million. Animal Health Adjusted EBITDA rose 6% to $127.4 million; Performance Products Adjusted EBITDA fell 63% to $1.0 million.
Net income benefited substantially from a $19.6 million release of the domestic deferred-tax valuation allowance and a $4.8 million benefit from previously unrecognized tax benefits. The reported effective tax rate was negative 7.8%; management states that the normalized future rate is expected to approximate 30%.
Liquidity, debt and balance sheet
- Cash and cash equivalents were $33.6 million at June 30, 2016, compared with $29.2 million in 2015.
- Working capital was $203.4 million, and the current-assets-to-current-liabilities ratio was 2.92:1.
- Total debt was $352.7 million, consisting primarily of a $284.2 million Term B loan and $69.0 million drawn on the revolving credit facility.
- The revolver commitment was increased to $200 million in January 2016. At year-end, $116.8 million remained available after borrowings and letters of credit.
- The Term B loan matures in April 2021 and the revolver matures in April 2019. The company reported compliance with debt covenants at year-end.
- Operating cash flow fell because inventories, accounts receivable and other assets absorbed cash. Investing cash use included $36.4 million of capital expenditures and $46.6 million for the MVP acquisition.
- The company expects approximately $30 million of capital expenditures in fiscal 2017 and believes cash, operating cash flow and financing availability will meet expected needs, subject to operating performance and covenant compliance.
Material changes versus the prior comparable period
- Revenue was essentially flat overall, but underlying sales increased approximately 1% excluding the $8.0 million vaccine-licensing milestone recorded in fiscal 2015.
- Excluding that prior-year milestone and current-year acquisition-related items, Animal Health sales increased approximately 5% and Adjusted EBITDA increased approximately 14%.
- Gross margin improved due to volume growth, operating efficiencies, lower material costs and favorable currency movements, partly offset by acquisition-related costs and vaccine manufacturing interruptions.
- SG&A increased 5% to $153.3 million, driven by acquisition-related compensation and transaction costs, higher sales-force and product-development spending, and increased environmental remediation costs.
- Interest expense increased 16% to $16.6 million because of higher revolver borrowings and acquisition-related accrued interest.
- In January 2016, Phibro acquired MVP Laboratories’ livestock vaccine business for approximately $46.6 million in cash, adding $8.5 million of goodwill and $28.4 million of definite-lived intangible assets.
- The company revised prior-year expense classifications, moving product-related intangible amortization from SG&A to cost of goods sold. The revisions affected gross profit presentation but did not affect previously reported net income or cash flows.
Outlook, commentary, risks and unusual items
- Management cites expected global animal-health market growth, emerging-market expansion, new products and product-lifecycle extensions as growth drivers.
- Antibacterials are a significant exposure: global MFAs and related sales were approximately $340 million, or about 45% of total sales. U.S. sales of FDA-classified medically important antibacterials were approximately $37 million.
- The FDA began steps in April 2016 to withdraw approval of Mecadox, citing potential carbadox-residue concerns. U.S. Mecadox sales were approximately $15 million in fiscal 2016. The company submitted supporting safety studies in July 2016, but the FDA response timing was not predetermined.
- The company estimates that withdrawal of all U.S. non-therapeutic claims for certain medically important antibacterials, without replacement therapeutic claims, could have reduced fiscal 2016 MFA sales by approximately $7 million.
- Phibro received FDA Form 483 observations following a March 2016 cGMP audit of its Guarulhos, Brazil facility and expects a possible follow-up inspection. Failure to satisfy cGMP requirements could materially affect operations.
- The company remains exposed to regulatory restrictions, antimicrobial-resistance concerns, product liability, animal-disease outbreaks, competition, raw-material volatility, foreign-exchange movements and operating risks in Israel and Brazil.
- Environmental accruals were $7.0 million at June 30, 2016, and outstanding letters of credit included $9.9 million supporting environmental financial assurance. Potential liability related to the Omega Chemical Superfund groundwater plume cannot be estimated with reasonable certainty.
- The company has two material weaknesses in internal control over financial reporting involving formal transaction-processing controls and access segregation. Management began remediation but could not determine when remediation would be complete.
- Subsequent events include an estimated $6.7 million pension curtailment gain expected in the September 2016 quarter and a potential pension-settlement charge of up to $3.0 million expected in the December 2016 quarter.
- Quarterly dividends of $0.10 per share were paid during fiscal 2016, and the board declared another $0.10 per share dividend payable September 28, 2016. Future dividends remain subject to board approval, financial condition and debt restrictions.
Important facts for investors to verify
- Resolution and potential financial impact of the FDA’s Mecadox withdrawal proceedings.
- Status of FDA remediation and follow-up inspections at the Guarulhos facility.
- Progress in remediating the two material weaknesses and implications for financial-reporting reliability.
- Normalized tax expense after the fiscal 2016 valuation-allowance release and discrete tax benefits.
- Cash conversion, inventory and receivables growth, and the sustainability of operating cash flow after elevated capital spending and the MVP acquisition.
- Debt maturities, floating-rate exposure and covenant headroom, including the effect of a 100-basis-point LIBOR increase, estimated by the company to raise annual interest expense by approximately $2.0 million.
- Potential environmental, litigation and regulatory liabilities, particularly the Omega Chemical matter and related indemnification claims.
- Future demand and pricing for antibacterials, Mineral Nutrition products and Performance Products, including the effect of commodity prices and customer consolidation.